Recursion Pharmaceuticals, Inc. RXRX Debt Repayments
Debt Repayments at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s debt repayments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s debt repayments?
- Recursion Pharmaceuticals, Inc. (RXRX) reported debt repayments of $2.21M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s debt repayments changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s debt repayments increased by 7.9% year-over-year, from $2.05M to $2.21M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s debt repayments?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s debt repayments has grown at a -9.9% compound annual growth rate (CAGR), from $12.8M to $8.43M.
- What does debt repayments mean?
- Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.